Eisai Submits New Drug Application For Donepezil Hydrochloride (U.S./Western Europe Registered Trademark: ARICEPT) to the Japanese Ministry of Health and Welfare
Tokyo (August 6, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) announced the submission of a new drug application for donepezil hydrochloride (U.S./WESTERN EUROPE registered trademark ARICEPT) to the Japanese Ministry of Health and Welfare on July 31st.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of about $2.3 billion in 1997 with approximately 16 percent of sales spent for research and development.
ARICEPT is a trademark of Eisai Co., Ltd.